CoChat

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Various forms of immunotherapy, such as checkpoint blockade immunotherapy, are proving to be effective at restoring T cell-mediated immune responses that can lead to marked and sustained clinical responses, but only in some patients and cancer types 1-4. Patients and tumours may respond unpredictably to immunotherapy partly owing to heterogeneity of the immune composition and phenotypic profiles of tumour-infiltrating lymphocytes (TILs) within individual tumours and between patients 5,6. Although there is evidence that tumour-mutation-derived neoantigen-specific T cells play a role in tumour control 2,4,7-10, in most cases the antigen specificities of phenotypically diverse tumour-infiltrating T cells are largely unknown. Here we show that human lung and colorectal cancer CD8+ TILs can not only be specific for tumour antigens (for example, neoantigens), but also recognize a wide range of epitopes unrelated to cancer (such as those from Epstein-Barr virus, human cytomegalovirus or influenza virus). We found that these bystander CD8+ TILs have diverse phenotypes that overlap with tumour-specific cells, but lack CD39 expression. In colorectal and lung tumours, the absence of CD39 in CD8+ TILs defines populations that lack hallmarks of chronic antigen stimulation at the tumour site, supporting their classification as bystanders. Expression of CD39 varied markedly between patients, with some patients having predominantly CD39- CD8+ TILs. Furthermore, frequencies of CD39 expression among CD8+ TILs correlated with several important clinical parameters, such as the mutation status of lung tumour epidermal growth factor receptors. Our results demonstrate that not all tumour-infiltrating T cells are specific for tumour antigens, and suggest that measuring CD39 expression could be a straightforward way to quantify or isolate bystander T cells.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41586-018-0130-2

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 1,370

Metadata

Authors
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., Duan, K., Ang, N., Poidinger, M., Lee, Y. Y., Larbi, A., Khng, A. J., Tan, E., Fu, C., Mathew, R., Teo, M., Lim, W. T., Toh, C. K., Ong, B.-H., Koh, T., Hillmer, A. M., Takano, A., Lim, T. K. H., Tan, E. H., Zhai, W., Tan, D. S. W., Tan, I. B., & Newell, E. W.
Affiliations
  • Agency for Science, Technology and Research (SG)
  • National Cancer Centre Singapore (SG)
  • Singapore General Hospital (SG)
  • National Heart Centre Singapore (SG)
Corresponding author
  • Simoni, Yannick
  • Newell, Evan W.
Venue
Nature
Published
2018-05
Volume
557
Issue
7706
Pages
575-579
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2804073610
Cited by
1,370
References
55
Citations by year
2026: 111 · 2025: 160 · 2024: 173 · 2023: 187 · 2022: 220 · 2021: 211 · 2020: 172 · 2019: 101 · 2018: 35
FWCI
48.96
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
tumor-infiltrating lymphocytes, CD39, lung cancer, colorectal cancer, neoantigens, tumor mutational burden, EGFR mutation, immune checkpoint blockade
MeSH terms
Antigens, Neoplasm, Antigens, Viral, Apyrase, Cell Separation, Humans, Lung Neoplasms, Phenotype, Colorectal Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Bystander Effect, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.